

Dr. Dibakar Podder

MD; DM; Post doctoral fellow

ASSOCIATE CONSULTANT

Department of Clinical Hematology and Cellular Therapies

TATA MEDICAL CENTER

dibakar.hematology@gmail.com

Education

MBBS, Agartala Government Medical College, Agartala

August 2005 — January 2010

MD (Pathology), Kasturba Medical College, Manipal, Udupi

May 2012 — May 2015

Post Doctoral Fellowship, Tata Medical Center, Kolkata

February 2016 — June 2018

DM (Clinical Hematology), Medical College and Hospital, Kolkata

August 2018 — August 2021

Professional Experience

Assistant Professor (Tripura Medical College), Tripura

September 2016 — February 2016

Department of Pathology

Junior Consultant (CNCI), Kolkata

October 2021 — February 2022

Department of Hematology-Oncology

Clinical Associate (Tata Medical Center), Kolkata

March 2022 — December 2022

Department of Clinical Hematology and Cellular Therapies

Junior Consultant, (Tata Medical Center), Kolkata

January 2023 — January 2024

Department of Clinical Hematology and Cellular Therapies

Associate Consultant, (Tata Medical Center), Kolkata

January 2024- present

Department of Clinical Hematology and Cellular Therapies

Conference Papers:

1. Pineal gland tumors- a report of two cases. NEUROPATH CME; 2014
2. Clinicopathologic and radiologic features of thymoma in 10 cases based on 2004 who classification- Annual Pathology conference, Goa; 2015
3. Cytopathology of mucoepidermoid carcinoma of salivary glands
4. Clinicopathological Characteristics and Outcome in Patients of Primary CNS Lymphoma Treated with Modified De-Angelis Protocol: An Audit; SOHO 2018
5. Case series of hairy cell leukemia- a rare low-grade b cell lymphoma with

Dr. Dibakar Podder

MD; DM; Post doctoral fellow

ASSOCIATE CONSULTANT

Department of Clinical Hematology and Cellular Therapies

TATA MEDICAL CENTER

dibakar.hematology@gmail.com

Education

MBBS, Agartala Government Medical College, Agartala

August 2005 — January 2010

MD (Pathology), Kasturba Medical College, Manipal, Udupi

May 2012 — May 2015

Post Doctoral Fellowship, Tata Medical Center, Kolkata

February 2016 — June 2018

DM (Clinical Hematology), Medical College and Hospital, Kolkata

August 2018 — August 2021

Professional Experience

Assistant Professor (Tripura Medical College), Tripura

September 2016 — February 2016

Department of Pathology

Junior Consultant (CNCI), Kolkata

October 2021 — February 2022

Department of Hematology-Oncology

Clinical Associate (Tata Medical Center), Kolkata

March 2022 — December 2022

Department of Clinical Hematology and Cellular Therapies

Junior Consultant, (Tata Medical Center), Kolkata

January 2023 — January 2024

Department of Clinical Hematology and Cellular Therapies

Associate Consultant, (Tata Medical Center), Kolkata

January 2024- present

Department of Clinical Hematology and Cellular Therapies

Conference Papers:

1. Pineal gland tumors- a report of two cases. NEUROPATH CME; 2014
2. Clinicopathologic and radiologic features of thymoma in 10 cases based on 2004 WHO classification- Annual Pathology conference, Goa; 2015
3. Cytopathology of mucoepidermoid carcinoma of salivary glands
4. Clinicopathological Characteristics and Outcome in Patients of Primary CNS Lymphoma Treated with Modified De-Angelis Protocol: An Audit; SOHO 2018
5. Case series of hairy cell leukemia- a rare low-grade B cell lymphoma with

unusual presentation. BESHCON 2018

6. MPN with t lymphoblastic lymphoma associated with a novel cytogenetic abnormality- a case report: HEMATOCON 2019
7. Safety and Efficacy of low dose thalidomide in transfusion dependent E-beta Thalassemia. BESHCON 2021
8. BK virus reactivations in patients undergoing Allogeneic stem cell transplant-an audit. APBMT 2022
9. Efficacy and safety of Ponatinib in chronic phase CML- Real world data from a tertiary care center- HEMATOCON 2022
10. Clinical Characteristics and Outcome of Extranodal NK T-Cell Lymphoma Nasal Type: A Decade's Experience- SOHO 2024
11. Early Impressions With Use of BCMA-Directed Therapy: Elranatamab in Multiply Relapsed/Refractory Multiple Myeloma: A Safety and Efficacy Analysis in a Tertiary Cancer Center in India- SOHO 2024

Publications

1. Podder D, Monappa V, Shetty P. Soft tissue chondroma: a rare tumor presenting as cutaneous nodule. *Our Dermatol Online*. 2014;6(2):1-3
2. Nayak Deepak M, Manohar Chethan, Podder Dibakar, Kakkar Richa. EDTA- Induced lymphoid clumping in follicular lymphoma- a case report. *Int j clin surg adv* 2013; 1(2):12-15
3. VS, R., Podder D., H, M. et al. Primary Central Nervous System Lymphoma: Long-Term Treatment Clinicopathological Characteristics and Outcome in Patients of Primary CNS Lymphoma Treated with Modified De-Angelis Protocol: An Audit SOHO 2018 DOI: 10.1016/j.cml.2018.07.210 Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach. *Indian J Hematol Blood Transfus*(2021). <https://doi.org/10.1007/s12288-021-01444-7>
4. Kumar, J., Pincha, R., Radhakrishnan, V. S., Tamboli, N., Nag, A., Podder, D., Chattopadhyay, D., Bhawe, S. J., Das, S., Parihar, M., Rath, A., Vinarkar, S., Mukhopadhyay, S., Chakraborty, S., Mishra, D. K., Chandy, M., & Nair, R. (2023). Safety and Efficacy of Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Updated Data from an Ongoing Single Arm Phase-II Investigator- Initiated Clinical Trial (PRIME Study). *Blood*, 142(Supplement 1), 6713. <https://doi.org/10.1182/blood-2023-186903>
5. Shinde S, Guntiboina VA, Nag A, Podder D, Chattopadhyay D, Kumar J, Bhawe S, Mishra DK, Chandy M, Nair R. Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanter's nightmare! *Blood Cell Ther*. 2024 Mar 15;7(2):33-36. doi: 10.31547/bct-2023-025

Clinical trials

1. A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the mSafety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed/Advanced Lymphoma (ADITI-1). (Principal-Investigator)
2. POLARGO: A phase III, open-label, multicenter, randomized study

evaluating the safety and efficacy of Polatuzumab Vedotin in combination with Rituximab plus Gemcitabine plus Oxaliplatin (R-GemOx) versus R-GemOx alone in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma. **Co Investigator**

3. **ASHA-1:** A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients with Relapsed Advanced Lymphoma (AUR108-101) **Co Investigator**
4. **PACIFICA:** A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/ μ L) **Co Investigator**
5. **IM048:** A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Ibrandomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) **Co Investigator**
6. **Magnetism 7 :** A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation . **Co Investigator**
7. **DARVIVA:** A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy with BCD-264 and Darzalex® in Subjects with Relapsed and Refractory Multiple Myeloma. **Co Investigator**
8. **PRIME :** Effect of pomalidomide-bortezomib-dexamethasone induction on MRD status in patients with newly diagnosed multiple myeloma. **Co Investigator**
9. An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate its Safety in Indian Participants with Relapsed and Refractory Multiple Myeloma who have previously received at least 3 prior lines of therapy including an Immunomodulatory agent, a Proteasome Inhibitor and an Anti-CD38 antibody and have demonstrated disease progression on the last therapy. **(Co-Investigator)**
10. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma **(GOLSEEK-1) (Co-Investigator)**
11. A Double-Blind, Randomized clinical study of the efficacy and safety of monotherapy with BCD-264 and Darzalex® in subjects with Relapsed and Refractory Multiple Myeloma **(DARVIVA). (Co-Investigator)**

Interests

Hemoglobinopathies, Anemias, Bone marrow failure syndromes, Platelet and Coagulation disorders

Plasma cell neoplasms

Lymphomas


Leukemias

Stem cell transplant and Cellular therapies

Membership

1. Indian Society of Hematology & Blood transfusion (ISHBT)
2. American Society of Hematology (ASH)
3. Society Of Hematologic Oncology (SOHO)
4. European Society Of Medical Oncology (ESMO)
5. Indian Myeloma Academic Groupe (IMAGe)
6. International Myeloma Society

ORCID ID: <https://orcid.org/0000-0003-4486-5340>



2.9.26

Serial No : 1431

The Tripura State Medical Council

Bidurkanta Chowmuhani, Agartala - 799001



Certificate of Registration

I hereby certify that the following qualification/ additional qualifications as shown in column 5 has/have been entered in The Tripura State Medical Council Register.

Registration No : 001431

Date : 06.11.2021

Name	DR. DIBAKAR PODDER
Father's Name	Dillip Podder
Qualification as entered in the Tripura State Medical Council	M.B.B.S., A.G.M.C, Tripura University, 2011. M.D (Pathology), Manipal University, 2015.
Regd. No. Date and State Medical Council with which Registered.	Regn. No. 001431 dated 25.05. 2015 of The Tripura State Medical Council.
Additional Qualification entered in the Tripura State Medical Register.	D.M (Clinical Hematology) from West Bengal University of Health Sciences, 2021.
Address :	189, A.K. Road No. 7, Agartala, P.O : Ramnagar, Dist. : West Tripura, PIN - 799002.



Pinak
2.9.2026

IMPORTANT NOTICE

1. Report change of address and additional qualifications promptly.
2. All enquiries made by the Registrar should be answered without fail.
3. All persons Registered under the Tripura Medical Council, ACT, 2010 are legally qualified to practice in Tripura.
4. Shall abide by code of Medical Ethics framed from time to time.

Pinak
2.9.2026

(Dr. Pinak Prasad Debbarna)

Registrar-cum Secretary

The Tripura State Medical Council

Bidurkanta Chowmuhani, Agartala - 799001

Registrar-cum Secretary

The Tripura State Medical Council

Agartala - 799001



Enabling research by sharing knowledge

ICH E6 GCP

Dibakar Podder

ICH E6 GCP Investigator Site Training

ICH GOOD CLINICAL PRACTICE E6(R3)

100% Completion

100%

on

26/03/2026

This e-learning course has been formally recognised for GCP training purposes by the following organisations and institutions:



Enabling research by sharing knowledge

Podder
2.9.2.26

This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors.

Global Health Training Centre
globalhealthtrainingcentre.org/elearning

Certificate Number 608b6435-f7be-4124-a177-9778e104b749 Version number 0